Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vertex Pharmaceuticals Incorporated
With
Tibotec Pharmaceutical Limited
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic, genotype 1, hepatitis C with detectable HCV RNA
HIV-1 infection for \>6 months
Documentation of a liver biopsy within 1 year before the screening visit showing evidence of hepatitis (demonstrated by inflammation and/or fibrosis)
You may not be if
Previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C
Previous treatment with interferon or ribavirin
Evidence of hepatic decompensation in cirrhotic subjects
Subjects who have participated in a clinical study involving administration of an investigational drug within 2 months
Part A only: subjects who have been on a HAART regimen within 12 weeks before study start
Clareo Health | Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
